副教授,博士生导师,中山大学百人计划引进人才
研究方向
1. 抗登革热、乙肝等病毒药物的研发
2. 探针工具的设计合成
工作经历
2026.05 - 至今 中山大学生物安全学院 副教授
2022.09 – 2026.05 中山大学公共卫生学院(深圳) 副教授
2016.09 - 2022.08 美国德克萨斯大学医学部(UTMB)博士后
2015.05 - 2016.08 康龙化成(北京)新药技术有限公司 研究员
2014.07 - 2015.04 上海源力生物技术有限公司(江苏恒瑞医药公司子公司)研究员
教育经历
2009.09 - 2014.07 中国科学院上海药物研究所 药学化学 理学博士
2005.09 - 2009.07 中国药科大学 药学理科基地班 理学学士
承担项目
1.国家自然科学基金面上项目(2026-2029),在研,主持
2.中山大学“百人计划”启动项目(2022-2025),在研,主持
3.中山大学高校基本科研业务费青年教师培育项目(2024-2024),结题,主持
发表论文 :
- Pang, S.#, Qiu, X.#, Cai, Z., Zhong, Z., Jiang, H.*, Zhou, J.*, Xu, J.* Drug Discovery of Antiviral Inhibitors Targeting Dengue Virus NS4B Protein. ACS Infect Dis 2026, 12(5): 1555-1571.
- Huo, J., Chen, H., Qiu, X., Wang, G., Sánchez-Céspedes, J., Liu, K.*, Zhou, J.*, Xu, J.*Small-Molecule Strategies against Human Adenoviruses: Progress, Challenges, and Future Perspectives. J. Med. Chem. 2025,68(13): 13186-13217.
- Huo, J.#, Xiao, J.#, Zhang, Y.#, Qiu, X., Huang, X., Wang, G., Wang, J., Liu, K.*, Xu, J.*Salicylamide derivatives as potent HBV inhibitors: insights into structure–activity relationships. RSC Medicinal Chemistry 2025,16(7): 3158-3173.
- Xu, J.#, Shi, S.#, Liu, G., Xie, X., Li, J., Bolinger, A. A., Chen, H., Zhang, W., Shi, P. Y., Liu, H.*, Zhou, J.*Design, synthesis, and pharmacological evaluations of pyrrolo[1,2-a]quinoxaline-based derivatives as potent and selective sirt6 activators. Eur. J. Med. Chem. 2023,246: 114998.
- Xu, J., Xue, Y., Bolinger, A. A., Li, J., Zhou, M., Chen, H., Li, H., Zhou, J. Therapeutic potential of salicylamide derivatives for combating viral infections. Med. Res. Rev. 2023,43(4): 897-931.
- Xu, J.#; Kim, H.#; Dong, J.#; Chen, H.; Xu, J.; Ma, R.; Zhou, M.; Wang, T.; Shen, Q.*; Zhou, J.* Structure-activity relationship studies on O-alkylamino-tethered salicylamide derivatives with various amino acid linkers as potent anticancer agents. Eur J Med Chem 2022, 234, 114229.
- Samrat, S. K.#; Xu, J.#; Xie, X.; Gianti, E.; Chen, H.; Zou, J.; Pattis, J. G.; Elokely, K.; Lee, H.; Li, Z.; Klein, M. L.; Shi, P.-Y.; Zhou, J.*; Li, H.* Allosteric inhibitors of the main protease of SARS-CoV-2. Antiviral Res. 2022, 205, 105381.
- Li, Z. #; Xu, J.#; lang, Y. #; Wu, X., Hu, S., Samrat, S., Tharappel, A., Butler, D.; Song, Y.; Zhang, Q.-Y.; Zhou, J.; Li, H.*In vitro and in vivo characterization of erythrosin B and derivatives against Zika virus. Acta Pharm. Sin. B. 2021, 12, 1662-1670.
- Xu, J.; Xue, Y.; Zhou, R.; Shi, P.-Y.; Li, H.; Zhou, J.* Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. Med. Res. Rev. 2021, 41, 1375-1426.
- Xu, J.#; Berastegui-Cabrera, J.#; Carretero-Ledesma, M.; Chen, H.; Xue, Y.; Wold, E. A.; Pachón-Díaz, J.; Zhou, J.*; Sanchez-Cespedes, J.* Discovery of a small molecule inhibitor of human adenovirus capable of preventing escape from the endosome. Int. J. Mol. Sci. 2021, 22(4), 1617.
- Xu, J.#; Wu, W.#; Chen, H.; Xue, Y.; Bao, X.*; Zhou, J.* Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues potently inhibit respiratory syncytial virus (RSV) replication and RSV infection-associated inflammatory responses. Bioorg. Med. Chem. 2021, 39, 116157.
- Xu, J. #; Berastegui-Cabrera, J. #; Ye, N.; Carretero-Ledesma, M.; Pachón-Díaz, J.; Chen, H.; Pachón-Ibáñez, M. E.; Sánchez-Céspedes, J.*; Zhou, J.* Discovery of Novel Substituted N-(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide Analogues as Potent Human Adenovirus Inhibitors. J. Med. Chem. 2020, 63, 12830-12852.
- Xu, J. #; Berastegui-Cabrera, J.#; Chen, H.; Pachón, J.; Zhou, J.*; Sánchez-Céspedes, J.* Structure–Activity Relationship Studies on Diversified Salicylamide Derivatives as Potent Inhibitors of Human Adenovirus Infection. J. Med. Chem. 2020, 63, 3142-3160.
- Li, Z.#; Xu, J.#; Lang, Y.; Fan, X.; Kuo, L.; D’Brant, L.; Hu, S.; Samrat, S. K.; Trudeau, N.; Tharappel, A. M.; Rugenstein, N.; Koetzner, C. A.; Zhang, J.; Chen, H.; Kramer, L. D.; Butler, D.; Zhang, Q.-Y.; Zhou, J.*; Li, H.* JMX0207, a Niclosamide Derivative with Improved Pharmacokinetics, Suppresses Zika Virus Infection Both In Vitro and In Vivo. ACS Infect. Dis. 2020,6, 2616-2628.
- Xu, J.; Shi, P.-Y.; Li, H.; Zhou, J.* Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ACS Infect. Dis. 2020, 6, 909-915.
- Xu, J.#; Xie, X.#; Chen, H.; Zou, J.; Xue, Y.; Ye, N.; Shi, P.-Y.*; Zhou, J.* Design, synthesis and biological evaluation of spiropyrazolopyridone derivatives as potent dengue virus inhibitors. Bioorg. Med. Chem. Lett. 2020, 30, 127162.
- Xu, J.#; Xie, X.#; Ye, N.; Zou, J.; Chen, H.; White, M. A.; Shi, P.-Y.*; Zhou, J.* Design, Synthesis, and Biological Evaluation of Substituted 4,6-Dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3′-indoline]-2′,5(3H)-dione Analogues as Potent NS4B Inhibitors for the Treatment of Dengue Virus Infection. J. Med. Chem. 2019, 62, 7941-7960.
- Xu, J.#; Pachon-Ibanez, M. E.#; Cebrero-Cangueiro, T.#; Chen, H.; Sanchez-Cespedes, J.*; Zhou, J.* Discovery of niclosamide and its O-alkylamino-tethered derivatives as potent antibacterial agents against carbapenemase-producing and/or colistin resistant Enterobacteriaceae isolates. Bioorg. Med. Chem. Lett. 2019, 29, 1399-1402.
- Fan, X. #; Xu, J. #; Files, M.; Cirillo, J. D.; Endsley, J. J.; Zhou, J.; Endsley, M. A.* Dual activity of niclosamide to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis (Beijing). Tuberculosis (Edinb.) 2019, 116S, S28-S33.
- Xu, J.; Wold, E. A.; Ding, Y.; Shen, Q.; Zhou, J.* Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection. Molecules 2018, 23, 474.
- Xu, J. #; Ai, J. #; Liu, S.; Peng, X.; Yu, L.; Geng, M.*; Nan, F.* Design and synthesis of 3,3'-biscoumarin-based c-Met inhibitors. Org. Biomol. Chem. 2014, 12, 3721-3734.
- Li, Z.; Tharappel, A. M.; Xu, J.; Lang, Y.; Green, C. M.; Zhang, J.; Lin, Q.; Chaturvedi, S.; Zhou, J.; Belfort, M.; Li, H., Small-molecule inhibitors for the Prp8 intein as antifungal agents. . Proc. Natl. Acad. Sci. U. S. A. 2021,118, e2008815118.
- Liu, X.; Xu, J.; Zhou, J.; Shen, Q. Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance. Genes & Diseases.2021, 8, 448-462.
- Samrat, S. K.; Xu, J.; Li, Z.; Zhou, J.; Li, H. Antiviral Agents against Flavivirus Protease: Prospect and Future Direction. Pathogens 2022, 11,293.
- Yu, Y.; Yang, W.; Bilotta, A. J.; Yu, Y.; Zhao, X.; Zhou, Z.; Yao, S.; Xu, J.; Zhou, J.; Dann, S. M.; Li, Y.; Cong, Y. STING controls intestinal homeostasis through promoting antimicrobial peptide expression in epithelial cells. The FASEB Journal.2020,34, 15417-15430.
- Davis-Reyes, B. D.; Smith, A. E.; Xu, J.; Cunningham, K. A.; Zhou, J.; Anastasio, N. C. Subanesthetic Ketamine with an AMPAkine Attenuates Motor Impulsivity in Rats. Behav. Pharmacol. 2021, 32, 335-344.
Cummins, C. B.; Wang, X.; Xu, J.; Hughes, B. D.; Ding, Y.; Chen, H.; Zhou, J.; Radhakrishnan, R. S. Antifibrosis Effect of Novel Oridonin Analog CYD0618 Via Suppression of the NF-κB Pathway. J. Surg. Res. 2018, 232, 283-292.
招生信息
每年招收研究生1–2名左右。研究方向主要围绕抗病毒小分子药物的设计与合成、结构优化及生物活性评价开展,欢迎具有化学、药物化学等相关背景或对药物研发感兴趣的同学加入!联系方式:xujm37@mail.sysu.edu.cn。


